Treatment of Advanced Melanoma: Past, Present and Future

被引：20

作者：

Fujimura, Taku ^{[1
]}

Kambayashi, Yumi ^{[1
]}

Ohuchi, Kentaro ^{[1
]}

Muto, Yusuke ^{[1
]}

Aiba, Setsuya ^{[1
]}

机构：

[1] Tohoku Univ, Dept Dermatol, Grad Sch Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan

来源：

LIFE-BASEL | 2020年 / 10卷 / 09期

关键词：

metastatic melanoma; BRAF inhibitors; MEK inhibitors; immune checkpoints inhibitors; combination therapy; ADVANCED METASTATIC MELANOMA; LIGAND; EXPRESSION; INTERFERON-ALPHA; PHASE-III; JAPANESE PATIENTS; OPEN-LABEL; TARGETED THERAPY; SURVIVAL RATES; DOUBLE-BLIND; NIVOLUMAB;

D O I：

10.3390/life10090208

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such as dacarbazine, and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have become recognized as anchor drugs for treating advanced melanoma with or without additional combination drugs such as ipilimumab. In addition, v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitors in combination with mitogen-activated protein kinase kinase (MEK) inhibitors are among the most promising chemotherapeutic regimens for treating advanced BRAF-mutant melanoma, especially in patients with low tumor burden. Since anti-PD1 antibodies are widely applicable for the treatment of both BRAF wild-type and mutated advanced melanomas, several clinical trials for drugs in combination with anti-PD1 antibodies are ongoing. This review focuses on the development of the anti-melanoma therapies available today, and discusses the clinical trials of novel regimens for the treatment of advanced melanoma.

引用

页码：1 / 15

页数：15

共 50 条

[1] Cutaneous melanoma - Past, present, and future
Schaffer, JV
Rigel, DS
Kopf, AW
Bolognia, JL
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (01) : S65 - S69
[2] Uveal melanoma: The past, the present and the future
Ian G Rennie
[J]. Eye, 1997, 11 : 255 - 264
[3] Melanoma immunology: past, present and future
Parmiani, Giorgio
Castelli, Chiara
Santinami, Mario
Rivoltini, Licia
[J]. CURRENT OPINION IN ONCOLOGY, 2007, 19 (02) : 121 - 127
[4] The Past, Present, and Future of Melanoma Therapy
Kim, Kevin B.
[J]. ONCOLOGY-NEW YORK, 2013, 27 (05): : 391 - 393
[5] Immunotherapy of melanoma - past, present and future
Hersey, Peter
[J]. CANCER FORUM, 2005, 29 (02) : 90 - 92
[6] Melanoma immunotherapy: Past, present, and future
Saleh, F
Renno, W
Klepacek, N
Ibrahim, G
Asfar, S
Dashti, H
Romero, P
Dashti, A
Behbehani, A
[J]. CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (27) : 3461 - 3473
[7] Advanced Manufacturing: Past, Present and Future
Plumb, Steve
[J]. MANUFACTURING ENGINEERING, 2022, 169 (05): : 15 - 16
[8] ADVANCED EDUCATION - PAST, PRESENT, AND FUTURE
HAMBURGER, F
[J]. IRE TRANSACTIONS ON EDUCATION, 1959, 2 (02): : 31 - 37
[9] ADVANCED PLACEMENT - PAST, PRESENT, AND FUTURE
FRANKLIN, MP
[J]. EDUCATIONAL FORUM, 1965, 29 (03): : 349 - 353
[10] Immunotherapy of Human Melanoma: Past, Present, Future
Mortezaee, Keywan
Majidpoor, Jamal
[J]. CURRENT MEDICINAL CHEMISTRY, 2024,

← 1 2 3 4 5 →